Selvita and Ardigen will receive funding for the development of an AI-based high-content screening platform

Selvita S.A. one of the largest preclinical contract research organizations in Europe, has signed a grant agreement with the National Centre for Research and Development for the development of a cell-based phenotypic platform based on high content imaging system integrated with artificial intelligence data analysis for multiple therapeutic areas, including neuroinflammatory and fibrosis drug discovery (HiScAI – High Content Screening Artificial Intelligence).

source https://www.pharmatutor.org/pharma-news/2020/selvita-and-ardigen-will-receive-funding-for-the-development-of-an-ai-based-high-content-screening-platform